VC FundPuts its own capital into companiesActive · deal in last 18 monthsLAST VERIFIED Oct 2026 · 57 SOURCES

Wellington Partners

Also known as Wellington Partners Life Science Venture Capital Management GmbH, Wellington Partners Management GmbH, Wellington Partners Advisory AG, Wellington Partners Life Sciences VI GmbH & Co. KG

Munich life-science VC since 1998 (BaFin-supervised fund managers in Munich, advisory AG in Zurich); €590m raised for life-science funds, 58 investments; €2–20m tickets.

Munich life-science VC founded 1998 (offices Munich and Zurich). Not Wellington Management (US asset manager).

HEADQUARTERS: Munich, Germany
FOUNDED: 1998
AUM: —
OUTSIDE CAPITAL: Yes
TEAM LISTED: 19 people

Focus

STAGES: SeedSeries ASeries BGrowth
SECTORS: Biotech & Life Sciences HealthTech
ASSET MIX: Venture capital
GEOGRAPHY: Europe

Investment arms & vehicles

Wellington Partners Life Sciences VI GmbH & Co. KG (WPLS VI)
Current life-science fund (SFDR Art. 8 product); German Spezial-AIF externally managed by Wellington Partners Life Science Venture Capital Management GmbH (KID)
Wellington Partners Life Sciences SPV I GmbH & Co. KG
Single-asset vehicle investing in Amboss GmbH, same external AIFM (KID)
Wellington Partners Advisory AG
Zurich advisory company named in the website imprint

Overview

Wellington Partners is a European venture capital firm founded in 1998 that invests in early- and growth-stage life-science companies in therapeutics, medical devices, diagnostics and digital health. It reports €590 million raised for life-science funds, 58 life-science investments and 27 exits, IPOs and trade sales; its funds include WPLS III (€78m, 2007), WPLS IV (€85m, 2012), WPLS V (€210m, 2017) and the current Wellington Partners Life Sciences VI GmbH & Co. KG. Investors include the European Investment Fund, the European Investment Bank, family offices, trusts and insurers. The funds are German limited partnerships managed by Munich GmbHs supervised by BaFin; a Zurich advisory AG operates the website. Its former technology practice (Spotify, Xing, FreeNow) makes no new investments.

Investment thesis

Early- and growth-stage life-science investor in therapeutics, medical devices, diagnostics, digital health and industrial biotechnology from Germany, Europe and beyond; proactively sources deals and leads or co-leads rounds from early to expansion stage plus selected PIPEs, with tickets typically €2–20m and board-level support.

PORTFOLIO (41)

Actelion
Biotech & Life Sciences · Exited March 2001
Adrenomed
Biotech & Life Sciences
Advanced Medical Balloons (AMB)
HealthTech
Aignostics
HealthTech
Amboss
HealthTech
Atopix Therapeutics
Biotech & Life Sciences · Exited October 2012
Ayoxxa Biosystems
HealthTech
Carisma Therapeutics
Biotech & Life Sciences
Confo
Biotech & Life Sciences
CorFlow Therapeutics
Biotech & Life Sciences
Definiens
HealthTech · Exited June 2014
Dunad
Biotech & Life Sciences
eGenesis
Biotech & Life Sciences
ImCheck
Biotech & Life Sciences
Immatics
Biotech & Life Sciences
Invendo medical
HealthTech · Exited October 2017
iOmx
Biotech & Life Sciences
Koa Health
HealthTech
MinervaX
Biotech & Life Sciences
MMI
HealthTech
MTM Laboratories
HealthTech · Exited July 2011
Neuway
Biotech & Life Sciences
Nyra Health
HealthTech
ONWARD
HealthTech
Oxford Immunotec
HealthTech · Exited January 2021
Polares Medical
HealthTech
Quanta
HealthTech
Rigontec
Biotech & Life Sciences · Exited October 2017
Sapiens
HealthTech · Exited August 2014
SciRhom
Biotech & Life Sciences
Seamless Therapeutics
Biotech & Life Sciences
Sidekick
HealthTech
SIRS
Biotech & Life Sciences
SNIPR Biome
Biotech & Life Sciences
SphingoTec
HealthTech
STipe
Biotech & Life Sciences
Symetis
HealthTech · Exited May 2017
Themis Bioscience
Biotech & Life Sciences · Exited June 2020
TRiCares
HealthTech
UroMems
HealthTech
NUCLIDIUM
Biotech & Life Sciences · since 2025

People

Dr. Rainer Strohmenger
Managing Partner · source
Harald Keller
Managing Partner, CFO; managing director of Wellington Partners Advisory AG · source
Ernst Mannheimer
Managing Partner, Legal Counsel; managing director of Wellington Partners Advisory AG · source
Dr. Johannes Fischer
Managing Partner (joined 2020; Partner since 2023) · source
Sabine Kannegiesser
Partner (Finance/Controlling, Zurich) · source
Dr. Varun Gupta
Partner · source
Dr. Regina Hodits
Venture Advisor · source
Dr. Lisa Gartenmann
Manager · source
Dr. Robert Buschauer
Associate · source
Ulrike Spring
Sustainability Manager · source
Cornelia Huber
Finance Manager · source
Doris Gowik
Project Manager (press contact) · source
Prof. Dr. Erich Schlick
Venture Partner · source
Dr. Ulrich Granzer
Venture Partner · source
Dr. Mel Spigelman
Venture Partner · source
Dr. Wolfgang Baiker
Venture Partner · source
Stuart Essig, Ph.D.
Venture Partner · source
Dr. Bo Jesper Hansen
Venture Partner · source
Dr. Peter Hirth
Venture Partner · source

Frequently asked questions

Wellington Partners is a VC fund based in Munich, Germany, founded in 1998.

Yes. Wellington Partners invests its own capital in private companies.

Wellington Partners invests at Seed, Series A, Series B and Growth stages in Biotech & Life Sciences and HealthTech.

Wellington Partners's stated ticket size is €2M–€20M.

Key people at Wellington Partners include Dr. Rainer Strohmenger (Managing Partner), Harald Keller (Managing Partner, CFO; managing director of Wellington Partners Advisory AG), Ernst Mannheimer (Managing Partner, Legal Counsel; managing director of Wellington Partners Advisory AG) and Dr. Johannes Fischer (Managing Partner (joined 2020; Partner since 2023)).

Wellington Partners's investments include Actelion, Adrenomed, Advanced Medical Balloons (AMB), Aignostics, Amboss, Atopix Therapeutics, Ayoxxa Biosystems and Carisma Therapeutics, among others.

The most recent publicly reported investment by Wellington Partners is NUCLIDIUM (Series B extension (CHF 26.4m; co-led by existing investors incl. Wellington Partners)), announced in May 2026.

Yes. Wellington Partners manages capital from outside investors.